Zobrazeno 1 - 10 of 48 pro vyhledávání: '"Poudel-Neupane N"'
1
Akademický článek
NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10.
Autor: Fu, Meiling1 (AUTHOR), Li, Jinxin2 (AUTHOR), Xuan, Zuodong1 (AUTHOR), Zheng, Zeyuan1 (AUTHOR), Liu, Yankuo1 (AUTHOR), Zhang, Zeyi1 (AUTHOR), Zheng, Jianzhong1 (AUTHOR), Zhong, Min1 (AUTHOR), Liu, Bin1 (AUTHOR), Du, Yifan1 (AUTHOR), Zhang, Lei3 (AUTHOR) Drzhanglei@xmu.edu.cn, Sun, Huimin1,4 (AUTHOR) hmsun@xah.xmu.edu.cn
Publikováno v: Cell Communication & Signaling. 9/3/2024, Vol. 22 Issue 1, p1-16. 16p.
Zobrazit plný text záznamu
2
Akademický článek
USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair.
Autor: McCann JJ; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Vasilevskaya IA; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Poudel Neupane N; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Shafi AA; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., McNair C; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Dylgjeri E; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Mandigo AC; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Schiewer MJ; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Schrecengost RS; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Gallagher P; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Stanek TJ; Department of Biochemistry & Molecular Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., McMahon SB; Department of Biochemistry & Molecular Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Berman-Booty LD; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Ostrander WF Jr; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania., Knudsen KE; Department of Cancer Biology, Sidney Kimmel Medical College, Philadelphia, Pennsylvania. karen.knudsen@jefferson.edu.
Publikováno v: Cancer research [Cancer Res] 2020 Feb 01; Vol. 80 (3), pp. 430-443. Date of Electronic Publication: 2019 Nov 18.
Zobrazit plný text záznamu
3
Akademický článek
PARP-1 regulates DNA repair factor availability.
Autor: Schiewer MJ; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA karen.knudsen@jefferson.edu.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Mandigo AC; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Gordon N; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Huang F; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Gaur S; Cedars-Sinai Medical Center, Los Angeles, CA, USA., de Leeuw R; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Zhao SG; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA., Evans J; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA., Han S; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA., Parsons T; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA., Birbe R; Cooper University Health, Camden, NJ, USA., McCue P; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA., McNair C; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Chand SN; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Cendon-Florez Y; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Gallagher P; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., McCann JJ; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Poudel Neupane N; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Shafi AA; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Dylgjeri E; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Brand LJ; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA., Visakorpi T; University of Tampere, Tampere, Finland., Raj GV; UT Southwestern, Dallas, TX, USA., Lallas CD; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA., Trabulsi EJ; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA., Gomella LG; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA., Dicker AP; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Kelly WK; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Leiby BE; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA., Knudsen B; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Feng FY; Departments of Radiation Oncology, Urology, and Medicine, University of California, San Francisco, San Francisco, CA, USA., Knudsen KE; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2018 Dec; Vol. 10 (12).
Zobrazit plný text záznamu
4
Akademický článek
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Autor: Rusan M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Li K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Christensen CL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Abraham BJ; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts., Kwiatkowski N; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Buczkowski KA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Bockorny B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Chen T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rhee K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chen W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Terai H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tavares T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Kim TJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea., Hong SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Poudel-Neupane N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Silkes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mudianto T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tan L; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Shimamura T; Molecular Pharmacology and Therapeutics, Oncology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois., Meyerson M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts., Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts., Watanabe H; Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Young RA; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts., Wong KK; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Hammerman PS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. peter.hammerman@novartis.com.; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
Publikováno v: Cancer discovery [Cancer Discov] 2018 Jan; Vol. 8 (1), pp. 59-73. Date of Electronic Publication: 2017 Oct 20.
Zobrazit plný text záznamu
5
Akademický článek
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Autor: Adeegbe DO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Liu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts., Kamihara Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Aref AR; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts., Almonte C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dries R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Warner-Hatten T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Castrillon J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Yuan GC; Harvard Chan School of Public Health, Boston, Massachusetts., Poudel-Neupane N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Guerriero JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Han S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Awad MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jones SS; Acetylon Pharmaceuticals, Inc., Boston, Massachusetts., Hammerman PS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Bradner J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Quayle SN; Acetylon Pharmaceuticals, Inc., Boston, Massachusetts., Wong KK; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. kwok-kin.wong@nyumc.org.
Publikováno v: Cancer discovery [Cancer Discov] 2017 Aug; Vol. 7 (8), pp. 852-867. Date of Electronic Publication: 2017 Apr 13.
Zobrazit plný text záznamu
6
Akademický článek
USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Autor: Kuang, Xianghong1,2 (AUTHOR), Salinger, Andrew1,2 (AUTHOR), Benavides, Fernando1,2 (AUTHOR), Muller, William J.3,4,5 (AUTHOR), Dent, Sharon Y. R.1,2,6 (AUTHOR) sroth@mdanderson.org, Koutelou, Evangelia1,2 (AUTHOR) sroth@mdanderson.org
Publikováno v: PLoS ONE. 1/18/2024, Vol. 19 Issue 1, p1-19. 19p.
Zobrazit plný text záznamu
7
Akademický článek
Mogrol-mediated enhancement of radiotherapy sensitivity in non-small cell lung cancer: a mechanistic study.
Autor: Yin, Zhongbo, Zhang, Xuedong, Sun, Xiao, Huo, Yunlong, Ji, Nan, Chen, Keyan
Publikováno v: American Journal of Physiology: Cell Physiology; Jun2024, Vol. 326 Issue 6, pC1753-C1768, 16p
Zobrazit plný text záznamu
8
Akademický článek
HDAC6: A unique HDAC family member as a cancer target.
Autor: Kaur, Sumeet1 (AUTHOR), Rajoria, Prerna1 (AUTHOR), Chopra, Madhu1 (AUTHOR) mchopra@acbr.du.ac.in
Publikováno v: Cellular Oncology (2211-3428). Oct2022, Vol. 45 Issue 5, p779-829. 51p.
Zobrazit plný text záznamu
10
Akademický článek
SAGA-Dependent Histone H2Bub1 Deubiquitination Is Essential for Cellular Ubiquitin Balance during Embryonic Development.
Autor: El-Saafin, Farrah1 (AUTHOR) farrah.el-saafin@onjcri.org.au, Devys, Didier2,3,4,5 (AUTHOR) devys@igbmc.fr, Johnsen, Steven A.6 (AUTHOR) steven.johnsen@bosch-health-campus.com, Vincent, Stéphane D.2,3,4,5 (AUTHOR) vincent@igbmc.fr, Tora, László2,3,4,5 (AUTHOR) vincent@igbmc.fr
Publikováno v: International Journal of Molecular Sciences. Jul2022, Vol. 23 Issue 13, p7459-N.PAG. 12p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje